H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status — See source for full details.
$IKT
Price history, market instrument context, member research, and related headlines in one place.
IKT key statistics
NasdaqCMUSD
52-week range
$1.3337%$2.61
Latest session $1.72–$1.87Inhibikase Therapeutics, Inc. (IKT) is a stock instrument quoted on NasdaqCM in USD. The most recently published price is $1.80, up $0.04 (2.27%) from the previous close of $1.76. It has traded between $1.72 and $1.87 in the latest session. Over the past year it has ranged from $1.33 to $2.61, leaving it in the lower half of its 52-week range (37%). Reported volume for the session was 1.6M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Loading $IKT research…